Combined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies
Cancer Communications · 01.01.2026 · 46
DOI: 10.34133/cancomm.0065 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Communications, online erschienen am 10.11.2026. Verfasst von Ziye Li und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medic…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Radiosurgery. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, USTC Research Funds of the Double First-Class Initiative, Anhui Office of Philosophy and Social Science.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitor (ICI)-based chemoimmunotherapy has become a standard first-line treatment for patients with driver-negative metastatic non-small cell lung cancer (NSCLC), but the clinical benefit is limited. Radiotherapy has potential antitumor immunomodulatory effects, but the optimal dose and fractionation remain unclear.
Methods
This single-arm, multicenter, prospective, phase II trial enrolled patients with stage IV driver-negative NSCLC who received first-line chemoimmunotherapy. During the ICI maintenance phase, patients received hybrid dose-fraction radiotherapy (Hybrid-RT): stereotactic ablative body radiotherapy (SABR) to targetable lesions and low-dose radiotherapy (LDRT) to other sites. Patients restaged to stage III disease after chemoimmunotherapy received short-course hypofractionated radiotherapy to all residual lesions. The primary endpoint was 1-year progression-free survival (PFS) rate. The secondary endpoints included 1-year overall survival (OS) rate, objective response rate, and safety. Parallel preclinical mechanistic studies were performed in a murine model.
Results
A total of 83 patients were enrolled from 2022 May 9 to 2023 December 31. The 1-year PFS rate was 54.2% (median PFS 16.1 months; 95% confidence interval [CI] 11.4 to 19.2 months), meeting the primary endpoint. The 1-year OS rate was 83.1% (median OS 29.3 months; 95% CI 21.9 months to not reached), and treatment was well tolerated. Peripheral immune profiling showed posttreatment expansion of cytotoxic CD8 + T cells and natural killer (NK) cells associated with promising clinical efficacy. In the murine model, ICI plus Hybrid-RT (IHBRT) induced a division of labor between CD8 + T and NK cells. At LDRT lesions, it facilitated both C-X-C motif chemokine receptor 3 (Cxcr3)-mediated recruitment of cytotoxic CD8 + T cells and natural killer group 2 member D-mediated NK cell cytotoxicity. At SABR lesions, Cxcr3-mediated CD8 + T cells played a predominant role, whereas NK cells contributed minimally. Moreover, IHBRT suppressed secreted phosphoprotein 1 positive (Spp1 + ) macrophages and relieved immunosuppression.
Conclusions
Clinically, IHBRT demonstrates promising efficacy and a manageable safety profile in driver-negative metastatic NSCLC. Preclinically, it induces a functional division of labor between CD8 + T and NK cells to activate antitumor immune cytotoxicity, and suppresses Spp1 + macrophages, thereby relieving immunosuppression.
Trial registration
This trial was registered at ClinicalTrials.gov (Identifier: NCT05348668). Date of registration: 2022 April 26.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, P. R…
- Core Facility Center, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, P. R. China.
- Anhui Provincial Cancer Hospital, Hefei, Anhui, P. R. China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China…
- The Center of Radiation Oncology, Guoyang County People's Hospital, Bozhou, Anhui, P. R. China.
- Department of Oncology, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.
ORCID-Profile: Dong Qian
Förderung
- National Natural Science Foundation of China
- USTC Research Funds of the Double First-Class Initiative
- Anhui Office of Philosophy and Social Science
Zitieren
APA
Li, Z., Li, X., Wei, X., Cao, L., Zhang, J., Wang, J., He, Y., Hu, A., Liu, L., Yan, B., Wang, C., Li, H., Zeng, P., Cheng, J., Wang, A., Ma, J., Xia, H., Wu, H., Xia, D., …, & Qian, D. (2026). Combined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies. Cancer Communications, 46. https://doi.org/10.34133/cancomm.0065
Vancouver
Li Z, Li X, Wei X, Cao L, Zhang J, Wang J, et al. Combined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies. Cancer Communications. 2026;46. doi:10.34133/cancomm.0065
BibTeX
@article{Li2026,
author = {Li, Ziye and Li, Xiaoyang and Wei, Xiaoying and Cao, Lejie and Zhang, Junqiang and Wang, Jianguo and He, Yuan and Hu, Anqi and Liu, Lei and Yan, Bing and Wang, Congyu and Li, Hongxia and Zeng, Ping and Cheng, Jingjing and Wang, Anlin and Ma, Jun and Xia, Huailing and Wu, Haibo and Xia, Daqing and Jiang, Fengshou and Xie, Dan and Qian, Dong},
title = {Combined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies},
journal = {Cancer Communications},
year = {2026},
volume = {46},
doi = {10.34133/cancomm.0065}
}
EUVIMED